KERX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KERX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-13), Keryx Biopharmaceuticals's share price is $3.36. Keryx Biopharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2018 was $-0.82. Hence, Keryx Biopharmaceuticals's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Keryx Biopharmaceuticals's Price-to-Operating-Cash-Flow or its related term are showing as below:
Keryx Biopharmaceuticals's Cash Flow from Operations per share for the three months ended in Sep. 2018 was $-0.19. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2018 was $-0.82.
The historical data trend for Keryx Biopharmaceuticals's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keryx Biopharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | |||||||||||
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
Keryx Biopharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | |
Price-to-Operating-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Keryx Biopharmaceuticals's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Keryx Biopharmaceuticals's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Keryx Biopharmaceuticals's Price-to-Operating-Cash-Flow falls into.
Keryx Biopharmaceuticals's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
= | 3.36 | / | -0.819 | |
= |
Keryx Biopharmaceuticals's Share Price of today is $3.36.
Keryx Biopharmaceuticals's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.82.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Price-to-Operating-Cash-Flow Ratio | = | Market Cap | / | Cash Flow from Operations |
Thank you for viewing the detailed overview of Keryx Biopharmaceuticals's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Scott A Holmes | officer: Chief Financial Officer | C/O KERYX BIOPHARMACEUTICALS INC 1 MARINA PARK DR., 10TH FLOOR BOSTON MA 02210 |
Daniel Paul Regan | director | C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013 |
Jodie Pope Morrison | director, officer: Interim CEO | C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142 |
Mark J Enyedy | director | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121 |
Michael Thomas Heffernan | director | C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
Steven C Gilman | director | 110 HARTWELL AVENUE, LEXINGTON MA 02421 |
Michael W Rogers | director | C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210 |
Baupost Group Gp, L.l.c. | 10 percent owner | 10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116 |
Baupost Group Llc/ma | director, 10 percent owner | 10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116 |
Seth A Klarman | 10 percent owner | 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116 |
Greg Madison | director, officer: President and CEO | ONE MARINA PARK DRIVE LEXINGTON MA 02210 |
Brian Adams | officer: General Counsel and Secretary | 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
John P. Butler | director | C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063 |
Sak Corp | 10 percent owner | 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116 |
Oliviero James F Iii | officer: Chief Financial Officer | C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
From GuruFocus
By Marketwired Marketwired • 10-01-2018
By InvestmentUnderground InvestmentUnderground • 04-12-2012
By Holly LaFon Holly LaFon • 10-12-2015
By Marketwired Marketwired • 05-30-2018
By PRNewswire PRNewswire • 10-02-2018
By Marketwired Marketwired • 11-07-2018
By Marketwired Marketwired • 04-11-2018
By Jimmy Xiao gurujx • 03-24-2014
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.